top of page

Stochastic Modeling of drug production demand

COMMERCIAL STRATEGY 

Stochastic modeling of drug demand

Problem & Background

HSG00186_HSG WEB 7.2-08.png

A US biotech company was developing a drug to treat multiple indications within oncology.  The company needed help understanding the total amount of drug needed over time for their planned clinical trials and commercial launches.

Our Approach

HSG00186_HSG WEB 7.2-10.png

We forecasted the total patients treated commercially and clinically in each planned indication, calculated the amount of drug needed per month based on total patients treated, treatment duration, etc., within each indication and region, and performed Monte Carlo analysis to understand the full range of demand based on key variables.

Value added

HSG00186_HSG WEB 7.2-09.png

We provided our client with confidence intervals of drug demand based on key clinical and commercial factors.

1Commercial Strategy
Commercial Strategy

Qualitatative Market Research & Revenue Forecast

COMMERCIAL STRATEGY 

Qualitative primary market research to inform revenue forecast

Problem & Background

HSG00186_HSG WEB 7.2-08.png

An early-stage microbiome company was interested in building an incidence & prevalence-based revenue forecast for their lead program to support upcoming fundraising discussions. Primary market research informed key assumptions for the rare and relatively niche indication in the forecast, including correct patient flow, epidemiology, market share, and pricing.

Our Approach

HSG00186_HSG WEB 7.2-10.png

We interviewed 6 KOLs, 6 payers, and 8 high-volume clinicians to inform our assumptions. Our model included incident and prevalent populations, numerous launch scenarios of competitors, and lastly, utilized Monte Carlo simulations to statistically predict the range of potential revenues based on uncertainties in key variables.

Value added

HSG00186_HSG WEB 7.2-09.png

We were able to provide a detailed commercial business case to our client to present in fundraising efforts.

2Commercial Strategy

Ex-US Commercialization Strategy

COMMERCIAL STRATEGY

Ex-US commercialization strategy for an oncology-focused US biotech

Problem & Background

HSG00186_HSG WEB 7.2-08.png

A clinical-stage oncology company was seeking to develop a commercialization strategy for their lead product outside the US. The company sought to understand and prioritize commercial opportunities in 7 ex-US markets.

Our Approach

HSG00186_HSG WEB 7.2-10.png

We leveraged primary and secondary market research to analyze and prioritize each of the 7 markets in Europe and Asia. We conducted interviews with commercial executives from each region and reviewed key literature, news, databases, and comparable companies to inform peak-year sales forecasts and prioritization framework for each market.

Value added

HSG00186_HSG WEB 7.2-09.png

We painted a detailed picture of the commercial risks and rewards involved in each ex-US market. Our findings informed launch order and partnering recommendations in each market, and the investment needed to pursue each strategic option.

6Commercial Strategy

Before/after storytelling slides

CORPORATE DEVELOPMENT

Storytelling to empower partnering, fundraising, and large collaborations

Problem & Background

HSG00186_HSG WEB 7.2-08.png

We serve many clients by creatively and collaboratively crafting strategic stories for communication to investors, board of directors, internal teams, and external partners.

Our Approach

HSG00186_HSG WEB 7.2-10.png

We use paid industry databases, graphing applications, and biology-specific graphic software to create easy to follow slide decks while still honoring the complexity of the stories.

Value added

HSG00186_HSG WEB 7.2-09.png

Our storytelling work has contributed to the success of our clients with $25B in BD/M&A, $700M in private financing, and $1.2B in public IPO financing.

Corporate Development
1Corporate Development

CEO/BoD storytelling slides

CORPORATE DEVELOPMENT

Strategic storytelling for C-suites and Board of Directors.

Problem & Background

HSG00186_HSG WEB 7.2-08.png

After we complete strategic projects, many clients present the findings to their CEOs and BoDs. These slides need to highlight the approach, main findings, and strategic implications -- all supported by details in the appendix, but not bogging down the clarity of insights and recommendations.

Our Approach

HSG00186_HSG WEB 7.2-10.png

We start with storytelling, decision making, and persuasion best practices.  We add empathy and client context.  We align with our clients as to how much persuasion or controversy a particular recommendation may cause.  We use world-class designers to visually make the slides match the client's expectations and/or style guide.

Value added

HSG00186_HSG WEB 7.2-09.png

Our storytelling work has been used by clients making recommendations to CEOs and Boards that matter, such as pipeline investments/divestments, BD/M&A roadmaps, fundraising and/or partnering goals, and other growth strategy initiatives.

2Corporate Development

Strategic roadmap support

CORPORATE DEVELOPMENT

BD/M&A strategic roadmap, search, evaluation, and due diligence support

Problem & Background

HSG00186_HSG WEB 7.2-08.png

Our client needed to accelerate BD/M&A activity to expand their portfolio and hit growth targets.  They needed support building strategic alignment with executives, identifying, evaluating, and prioritizing potential deal targets and diseases, and building investment these (I.e., mini-TPPs) for each priority disease.

Our Approach

HSG00186_HSG WEB 7.2-10.png

Collaboratively, we built approaches that would best meet the client's needs.  We were sensitive to building alignment among executives and senior leadership.  We then applied hard-nosed strategic analysis to scour the potential target landscape.

Value added

HSG00186_HSG WEB 7.2-09.png

Over 12 months, our flexible, nimble, and collaborative work built alignment, evaluated numerous targets under due diligence, and supported a deal in IBD with a Top 20 Pharma partner.

3Corporate Development

Indication prioritization for single asset in oncology 

R&D / PORTFOLIO

Indication prioritization for single asset

Problem & Background

HSG00186_HSG WEB 7.2-08.png

A large pharmaceutical company with a small molecule program needed to identify and prioritize >15 oncology indications to invest in as line extensions. Many of the indications were outside their organizational expertise.

Our Approach

HSG00186_HSG WEB 7.2-10.png

We developed concise and informative disease overviews, TPPs, competitive landscapes, revenue forecasts, and risk-adjusted NPVs. We built a customized prioritization framework with qualitative and quantitative parameters -- spanning commercial, R&D, and corporate drivers -- to rank indications with a clear scoring rationale.

Value added

HSG00186_HSG WEB 7.2-09.png

As a result of our work, the client used the prioritization to guide investment in the top 3 indications from our collaborative analysis.

R&D / Portfolio
1R&D / Portfolio

Platform Strategy/Indication Prioritization

R&D / PORTFOLIO

Indication prioritization for platform-driven biotech

Problem & Background

HSG00186_HSG WEB 7.2-08.png

A biotech with an innovative platform needed help identifying rare diseases best suited for its technology, then evaluating those diseases in an apples-to-apples, rigorous manner.

Our Approach

HSG00186_HSG WEB 7.2-10.png

We deployed a custom filter to narrow a list of 20+ diseases to the top 10 with greatest potential.  We created a customized prioritization framework evaluating commercial, R&D, and corporate factors using secondary research and custom primary market research with KOLs.

Value added

HSG00186_HSG WEB 7.2-09.png

Our collaborative analysis led to the client selecting our top recommended indications for further investment.  Our analysis was used directly in Board and investor presentations to share their clarified corporate strategy.

2R&D / Portfolio

Imaging/clinical endpoint evaluation

R&D / Neurology / CNS

Drug development innovation through the use of novel imaging and AI/ML biomarkers in a neurology / CNS indication 

Problem & Background

HSG00186_HSG WEB 7.2-08.png

A biotech that had developed a novel, first-in-class therapeutic was seeking assistance in identifying, evaluating, and prioritizing novel imaging biomarkers to demonstrate the clinical benefits of their therapeutic vs. competition.  The disease was poorly understood, leaving the door open for innovation with endpoints.

Our Approach

HSG00186_HSG WEB 7.2-10.png

Together with the client, internal and KOL experts, and secondary research, we identified and/or created 80+ feasible, compelling digital biomarker endpoints, some of them involving groundbreaking technology. We created a robust prioritization process to systematically evaluate them in a stepwise fashion.

Value added

HSG00186_HSG WEB 7.2-09.png

Our collaborative output was endorsed by the lifecycle team and chief medical officer.  Some recommended endpoints were implemented within weeks to the ongoing trial with our direct interaction with CROs.  Other endpoints were prioritized for the upcoming pivotal trial.

3R&D / Portfolio
bottom of page